Sanofi Signs Sarclisa Deal for Canadian Myeloma Patients
The pan-Canadian Pharmaceutical Alliance has issued a Letter of Intent covering Sarclisa for newly diagnosed transplant-ineligible multiple myeloma.
Updated on Nov. 16, 2026 in Cancer

Live Poll
Should Canada's public health system cover new cancer drugs for patients quickly?
Sanofi completed negotiations with the pan-Canadian Pharmaceutical Alliance and signed a Letter of Intent for Sarclisa, given intravenously with bortezomib, lenalidomide and dexamethasone, for adults with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. Public coverage will follow once funding agreements are finalized with each province and territory.
Why it matters
Transplant-ineligible patients have historically had poorer long-term outcomes than transplant-eligible patients, and Health Canada authorized the treatment based on the IMROZ study. Multiple myeloma is the second most common blood cancer in Canada, so the funding pathway could affect a significant number of patients across the country.
In the IMROZ Phase 3 trial, 63% of patients receiving Sarclisa plus VRd were progression-free at about five years, compared with 45% on VRd alone, a 40% reduction in the risk of progression or death. Public funding timelines and eligibility details beyond the Letter of Intent have not yet been disclosed.
The players
Sanofi
A global pharmaceutical company headquartered in France, with a significant research and manufacturing presence in Canada, that markets Sarclisa.
pan-Canadian Pharmaceutical Alliance
A collaborative body that negotiates pricing and reimbursement of prescription drugs on behalf of Canada's provinces and territories, excluding Quebec.
The details
The Letter of Intent covers first-line use of Sarclisa intravenously in combination with bortezomib, lenalidomide and dexamethasone. The treatment is already approved in 56 countries worldwide, and the IMROZ study is the first global Phase 3 study of an anti-CD38 monoclonal antibody combined with VRd to significantly improve progression-free survival versus VRd alone.
Timeline
November 16, 2026: Sanofi announced completion of negotiations and signed the Letter of Intent with the pan-Canadian Pharmaceutical Alliance.
2026: An estimated 4,400 patients are expected to be diagnosed with multiple myeloma in Canada.
Health Landscape
The Sarclisa agreement builds on the IMROZ study, the first global Phase 3 trial of an anti-CD38 monoclonal antibody combined with VRd to significantly improve progression-free survival over VRd alone. It moves that evidence from Health Canada authorization toward public coverage for transplant-ineligible patients, a group that has historically faced worse long-term outcomes.
Eligible Canadians with newly diagnosed multiple myeloma who cannot receive a stem cell transplant would gain access to Sarclisa in combination with VRd once provincial and territorial funding is in place. Patients should discuss eligibility and timing with their hematologist as coverage details are finalized.
The takeaway
For patients ineligible for transplant, the IMROZ results suggest adding Sarclisa to standard combination therapy may meaningfully extend time without disease progression. Speaking with a hematologist about eligibility is the most practical next step once public coverage is confirmed.
What happens next
Public coverage of Sarclisa will follow once funding agreements are finalized with each province and territory, though no dates for those agreements have been announced.
Further reading
For more on related treatment developments, explore Cancer coverage on Wisevoter.
Source note: This article includes information reported by Elliotlakestandard.
Live Poll
Should Canada's public health system cover new cancer drugs for patients quickly?










